Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath
- 30 April 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 200 (4) , 505-515
- https://doi.org/10.1016/j.jamcollsurg.2004.12.024
Abstract
Background Multiple drug immunosuppression has allowed the near elimination of rejection, but without commensurate improvements in longterm graft survival and at the cost of quality of life. We have suggested that transplantation outcomes can be improved by modifying the timing and dosage of immunosuppression to facilitate natural mechanisms of alloengraftment and acquired tolerance. Study design Two therapeutic principles were applied for kidney transplantation: pretransplant recipient conditioning with antilymphoid antibody preparations (Thymoglobulin [Sangstat] or Campath [ILEX Pharmaceuticals]), and minimal posttransplant immunosuppression with tacrolimus monotherapy including “spaced weaning” of maintenance doses when possible. The results in Thymoglobulin- (n = 101) and Campath-pretreated renal transplantation recipients (n = 90) were compared with those in 152 conventionally immunosuppressed recipients in the immediately preceding era. Results Spaced weaning was attempted in more than 90% of the kidney transplant recipients after pretreatment with both lymphoid-depleting agents, and is currently in effect in two-thirds of the survivors. Although there was a much higher rate of acute rejection in the Thymoglobulin-pretreated recipients than in either the Campath-pretreated or historic control recipients, patient and graft survival in both lymphoid depletion groups is at least equivalent to that of historic control patients. In the Thymoglobulin-conditioned patients for whom followups are now 24 to 40 months, chronic allograft nephropathy (CAN) progressed at the same rate as in historic control patients. Selected patients on weaning developed donor-specific nonreactivity. Conclusions After lymphoid depletion, kidney transplantation can be readily accomplished under minimal immunosuppression with less dependence on late maintenance immunosuppression and a better quality of life. Campath was the more effective agent for pretreatment. Guidelines for spaced weaning need additional refinement.Keywords
This publication has 32 references indexed in Scilit:
- Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapyThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Thymoglobulin: an immunologic overviewCurrent Opinion in Organ Transplantation, 2003
- Kidney Transplantation Under a Tolerogenic Regimen of Recipient Pretreatment and Low-Dose Postoperative Immunosuppression With Subsequent WeaningAnnals of Surgery, 2003
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- IDENTIFICATION OF PATIENTS AT HIGH RISK OF GRAFT LOSS BY PRE- AND POSTTRANSPLANT MONITORING OF ANTI-HLA CLASS I IgG ANTIBODIES BY ENZYME-LINKED IMMUNOSORBENT ASSAYTransplantation, 1997
- BOTH ALLOANTIGEN-DEPENDENT AND -INDEPENDENT FACTORS INFLUENCE CHRONIC ALLOGRAFT REJECTIONTransplantation, 1995
- HISTOLOGICAL CHRONIC ALLOGRAFT DAMAGE INDEX ACCURATELY PREDICTS CHRONIC RENAL ALLOGRAFT REJECTIONTransplantation, 1994
- CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY DOES NOT CORRELATE WITH EITHER THE INCIDENCE OR SEVERITY OF GRAFT-VERSUS-HOST DISEASE AFTER MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION1Transplantation, 1994
- Optimising a limiting dilution culture system for quantitating frequencies of alloreactive cytotoxic T lymphocyte precursorsCellular Immunology, 1991
- SOLUBLE HLA ANTIGENS, ANTI-HLA ANTIBODIES, AND ANTIIDIOTYPIC ANTIBODIES IN THE CIRCULATION OF RENAL TRANSPLANT RECIPIENTSTransplantation, 1991